All News & Press Releases
15 May 2009
New intellectual property around the Interstitial NanoSystems pulmonary inhaler has been protected under the Australian provisional application 2009902063 Microfluidics apparatus for the atomisation of a liquid.
12 May 2009
Interstitial NanoSystems has reached agreement with Italian pharmaceutical company SARM Allergeni Srl. (SARM) to co-develop technology for the transdermal delivery of the anti-allergy reagent ‘Sarmexall’. Sarmexall is a new formulation designed to de-sensitize sufferers of allergies. Most de-sensitisation is delivered by injection, and the delivery via skin patches would reduce trauma for users, and increase usage.
 The Asthma and Allergy Foundation of America estimates that there are 29,000 anaphylactic reactions to foods treated in emergency departments and nearly 200 deaths due to food allergies In the US, each year. Seafood allergies - including scaly fish and shellfish (i.e. crustaceans and molluscs) - are the most common causes of food allergy. Seafood can be a powerful allergen for certain people, causing life-threatening reactions. Seafood allergies are life-long.
SARM is an allergy therapeutics company based in Rome, Italy, and has been operating in the pharmaceutical sector since 1924. SARM currently manufactures products for the prevention, diagnosis and treatment of allergies.
The Agreement completed in April 2009 is a co-development and licensing agreement. 11 May 2009
Dr Bob Irving, CEO of Interstitial NanoSystems, is a key speaker at a major US Biotechnology conference in mid May.
Bob, well known for his leadership of therapeutic development based on nanoparticles, will present at the 3rd Annual Drug Delivery Summit, from the 14th to the 15th of May 2009 in San Francisco.
Bob will present on The Challenges of Delivering Large Molecule Therapeutics: Nanotechnology Enhancements for Transdermal and Pulmonary Delivery.
Prominent speakers at the Summit include leaders from Merck, Johnson & Johnson, NanoCyte, Altea, and Aerogen
27 November 2008
Dr Bob Irving, CEO, Interstitial NanoSystems is a member of the Scientific Advisory Board for the upcoming commercial and applications based BIT Life Sciences 1st Annual International Congress of Antibody to be held in Beijing, May 22nd-24th 2009. Dr Irving will be presenting the molecular evolution and diagnostic activities entitled “The applications of antibodies to nanotechnology-based diagnostics, targeting and nanoarrays”. Further information can be found on the Congress website.
13 November 2008
An article around the Interstitial NS nVac technology has been published in the October on-line edition of the journal Vaccine. The research, led by Prof Colin Pouton and Dr Paul White from Monash Pharmacy and Pharmaceutical Sciences, entitled Generic construction of single component particles that elicit humoural and cellular immune responses without the need for adjuvants highlights the advantages of nanoformulated vaccines.
13 November 2008
Dr Bob Irving and Dr Michelle Critchley of Interstitial NanoSystems will be attending the Sir Mark Oliphant Inaugural Conference on Medical Bionics.
More…
13 November 2008
Leah Heiss will be holding a solo exhibition of her previous and current work with NanoVic and Interstitial NanoSystems at the RMIT Gallery, Melbourne, from November 6th - 27th.
More…
15 August 2008
Dr Bob Irving of Nanotechnology Victoria Ltd (NanoVic) and Interstitial NanoSystems and Dr Shin-Hwan Wang of DR. Chip Biotechnology Inc., Taiwan have signed an MOU in Hsinchu, Taiwan for potential future activities and cross-licensing opportunities in the fields of Nano Arrays and Diagnostic Biochips.
More…
11 July 2008
The Interstitial NS NanoMAP product has been highlighted in an Article in the journal Industrial Pharmacy. The article Nanotechnology Advances in Drug Delivery Methods: Transdermal Delivery with Micro-array Patches gives an overview of the technology for the non-invasive delivery of nanoparticulate drugs and vaccines.
2 July 2008
The Micro/Nano Physics Research Laboratory at Monash University was officially opened last night by Innovation Minister Hon Gavin Jennings. The MNRL is a state-of-the-art facility within the Monash University Biological Engineering Department. More…
« Previous Entries
|
